Navigation Links
Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA

INDIANAPOLIS and PHILADELPHIA, Jan. 20, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee decided today that it could not recommend approval of Amyvid™ (florbetapir) at this time based on the currently available data (13-3); but, voted unanimously (16-0) to recommend approval of Amyvid conditional on a reader training program that demonstrates reader accuracy and consistency through a re-read of previously acquired scans. The Committee supported that efficacy was established and there were no significant safety concerns raised.

Amyvid is a molecular imaging tool under investigation for the detection of beta-amyloid plaque in the brain. The Committee stated that a negative scan would be clinically useful in indicating that Alzheimer's pathology is unlikely to be the cause of a patient's cognitive decline.

Lilly acquired Avid Radiopharmaceuticals, Inc. in December 2010. Amyvid is Avid's lead candidate and was the first beta-amyloid imaging compound to enter multi-center, investigational new drug (IND) clinical studies in the United States. Amyvid was recently assigned priority review designation by the FDA.

"We appreciate the careful and thoughtful review of our data today by the Committee," said Daniel M. Skovronsky, M.D., Ph.D., CEO, Avid Radiopharmaceuticals, Inc. "We are encouraged that they recommended a clear path toward approval."

The FDA will consider the panel's recommendation in its review of Amyvid. The FDA takes the advice of its Advisory Committees into consideration when reviewing investigational drugs, but is not bound by their recommendations.

About Amyvid

Amyvid is an imaging tool indicated for Positron Emission Tomography (PET) imaging of beta-amyloid plaque in the brain. It's being investigated for the potential use in ruling out Alzheimer's disease. In addition to the pivotal Phase III "Image-to-Autopsy" study, other clinical studies are also being conducted in the E.U., North and South America, Australia and Asia.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at  


This press release contains forward-looking statements about Amyvid (Florbetapir) for use as a molecular imaging tool for the detection of beta-amyloid plaque in the brain. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that florbetapir will be approved by the FDA on the anticipated timeline or at all, or that that it, will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements.


SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
2. Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
3. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
4. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
5. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
6. PhRMA Statement on Department of Homeland Security Efforts to Crack Down on Counterfeiting Crimes
7. Lilly Statement Regarding President Obamas Meeting With U.S. Business Leaders
8. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
9. ERT Files Shelf Registration Statement
10. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
11. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti
Post Your Comments:
(Date:10/13/2015)... 2015  Graduate students across the country, with ... will soon have the opportunity to learn about ... drug discovery and development process. Eli Lilly and ... 10 leaders from academic institutions to create an ... of Drug Development."  Lilly will formally unveil the ...
(Date:10/13/2015)... 13, 2015 anesthesia and respiratory ... billion by 2022, according to a new report by ... to their capability to resolve various environmental and lifestyle ... growth. --> anesthesia and respiratory devices market ... 2022, according to a new report by Grand View ...
(Date:10/13/2015)... 2015   Micell Technologies , Inc. today announced ... trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary ... presented at the 27th Annual Transcatheter Cardiovascular Therapeutics ( ... , October 11-15. TCT is the world,s largest ... was designed to optimize vessel healing in patients with ...
Breaking Medicine Technology:
(Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 ... ... growing natural beverage companies in the United States, today announced the release of ... Brew Coffee, and new Cranberry Cocktail Agua Fresca. All feature the unique flavor ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology company ... health programs and interventions via mobile devices that provide a framework for the ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ProText ... Pro X . With ProText Kinetic Panel, users can create energetic text animations in ... a preset into the Final Cut Pro X timeline and stylize the text. With ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Symposium Chairman, ... the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. ... immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , Key ...
(Date:10/13/2015)... PA (PRWEB) , ... October 13, 2015 , ... In ... 2015 utility costs were 36 percent lower per square foot than in 2009. The ... actual cost of heating and cooling has decreased by eight percent. , According ...
Breaking Medicine News(10 mins):